(25)
15 Juli 2016 - 10:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR
REGISTRATION UNDER SECTION 12(b) OF THE
SECURITIES EXCHANGE ACT OF 1934
Commission File Number 001-35642
GlobeImmune,
Inc.
The NASDAQ Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
1450 Infinite Drive
Louisville, CO 80027
Telephone: (303) 625-2700
(Address, including zip code, and telephone number, including area code, of Issuers principal executive offices))
Common Stock, par value $0.001 per share
(Description of class of securities)
Please place an X in the box to
designate the rule provision relied upon to strike the class of securities from listing and registration:
¨
|
17 CFR 240.12d2-2(a)(1)
|
¨
|
17 CFR 240.12d2-2(a)(2)
|
¨
|
17 CFR 240.12d2-2(a)(3)
|
¨
|
17 CFR 240.12d2-2(a)(4)
|
¨
|
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.
|
x
|
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and
registration on the Exchange.
|
Pursuant to the requirements of the Securities Exchange Act of 1934, GlobeImmune, Inc. certifies that it has
reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
|
|
|
|
|
|
|
|
|
July 15, 2016
|
|
By:
|
|
/s/ Timothy C. Rodell
|
|
|
|
Chief Executive Officer and President
|
Date
|
|
|
|
Name
|
|
|
|
Title
|
Globelmmune (CE) (USOTC:GBIM)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Globelmmune (CE) (USOTC:GBIM)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
Echtzeit-Nachrichten über Globelmmune Inc (CE) (OTCMarkets): 0 Nachrichtenartikel
Weitere Globeimmune Inc News-Artikel